2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society

J Am Coll Cardiol. 2014 Dec 2;64(21):e1-76. doi: 10.1016/j.jacc.2014.03.022. Epub 2014 Mar 28.

Abstract

No abstract available

Keywords: AHA Scientific Statements; atrial fibrillation; cardio-renal physiology/pathophysiology; cardiovascular surgery: transplantation, ventricular assistance, cardiomyopathy; epidemiology; full revision; health policy and outcome research; other atrial fibrillation.

Publication types

  • Practice Guideline
  • Review

MeSH terms

  • Anti-Arrhythmia Agents / therapeutic use
  • Anticoagulants / therapeutic use
  • Arrhythmias, Cardiac / physiopathology
  • Atrial Fibrillation / classification
  • Atrial Fibrillation / physiopathology
  • Atrial Fibrillation / therapy*
  • Autonomic Nervous System / physiopathology
  • C-Reactive Protein / analysis
  • Cardiac Output, Low / physiopathology
  • Catheter Ablation
  • Comorbidity
  • Defibrillators, Implantable
  • Echocardiography, Transesophageal
  • Electric Countershock
  • Electrocardiography
  • Fibrinolytic Agents / therapeutic use
  • Heart Atria / abnormalities
  • Heart Atria / physiopathology
  • Heart Atria / surgery
  • Heart Conduction System / physiopathology
  • Humans
  • Inflammation / physiopathology
  • Natriuretic Peptide, Brain / blood
  • Oxidative Stress / physiology
  • Pacemaker, Artificial
  • Platelet Aggregation Inhibitors / therapeutic use
  • Renin-Angiotensin System / physiology
  • Risk Assessment
  • Risk Factors
  • Septal Occluder Device
  • Stroke / etiology
  • Stroke / prevention & control
  • Thromboembolism / physiopathology
  • Thromboembolism / prevention & control
  • Ventricular Remodeling / physiology

Substances

  • Anti-Arrhythmia Agents
  • Anticoagulants
  • Fibrinolytic Agents
  • Platelet Aggregation Inhibitors
  • Natriuretic Peptide, Brain
  • C-Reactive Protein